Table of Content

1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Anti-obesity Drugs Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)

2 Executive Summary

3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Increasing Prevalence of Obesity
3.2.1.2 Growing Awareness of Health Risks Associated with Obesity
3.2.1.3 Technological Advancements
3.2.1.4 Favourable Government Policies to Address Obesity Epidemic
3.2.2 Market Restraining Factors
3.2.2.1 Adverse Drugs Reactions Associated with Anti-obesity Drugs
3.2.2.2 Adherence to Weight Management Medications
3.2.2.3 Lack of Access to Affordable Anti-obesity Drugs
3.2.3 Market Opportunities
3.2.3.1 Increasing Number of Individuals Grappling with Obesity
3.2.3.2 Automation in Drug Development Technologies
3.2.3.3 Utilization of Digital Platforms to Enhance Patient Engagement
3.3 Anti-obesity Drugs Analysis
3.3.1 Top Anti-obesity Products, by Revenue
3.3.2 Pipeline Analysis by Phase
3.3.3 New Product Launches
3.4 COVID-19 Impact Analysis
3.5 Porter’s Five Forces Analysis
3.5.1 Bargaining Power of Suppliers
3.5.2 Bargaining Power of Buyers
3.5.3 Competitive Rivalry
3.5.4 Threat of Substitutes
3.5.5 Threat of New Entrants
3.6 PEST Analysis

4 Anti-obesity Drugs Market Analysis by Drug Type
4.1 Key Findings
4.2 Drug Type Segment: Market Attractiveness Index
4.3 Anti-obesity Drugs Market Size Estimation and Forecast by Type
4.4 Prescription
4.4.1 Market Size by Region, 2024-2034 (US$ Million)
4.4.2 Market Share by Region, 2024 & 2034 (%)
4.5 OTC
4.5.1 Market Size by Region, 2024-2034 (US$ Million)
4.5.2 Market Share by Region, 2024 & 2034 (%)

5 Anti-obesity Drugs Market Analysis by Mechanism of Action
5.1 Key Findings
5.2 Drug Type Segment: Market Attractiveness Index
5.3 Anti-obesity Drugs Market Size Estimation and Forecast by Mechanism of Action
5.4 GLP-1 Agonists
5.4.1 Market Size by Region, 2024-2034 (US$ Million)
5.4.2 Market Share by Region, 2024 & 2034 (%)
5.5 GIPR Antagonists
5.5.1 Market Size by Region, 2024-2034 (US$ Million)
5.5.2 Market Share by Region, 2024 & 2034 (%)
5.6 Amylin Receptor Agonist
5.6.1 Market Size by Region, 2024-2034 (US$ Million)
5.6.2 Market Share by Region, 2024 & 2034 (%)
5.7 Lipase Inhibitors
5.7.1 Market Size by Region, 2024-2034 (US$ Million)
5.7.2 Market Share by Region, 2024 & 2034 (%)
5.8 SNRI’s
5.8.1 Market Size by Region, 2024-2034 (US$ Million)
5.8.2 Market Share by Region, 2024 & 2034 (%)
5.9 Others
5.9.1 Market Size by Region, 2024-2034 (US$ Million)
5.9.2 Market Share by Region, 2024 & 2034 (%)

6 Anti-obesity Drugs Market Analysis by Route of Administration
6.1 Key Findings
6.2 Route of Administration Segment: Market Attractiveness Index
6.3 Anti-obesity Drugs Market Size Estimation and Forecast by Route of Administration
6.4 Oral
6.4.1 Market Size by Region, 2024-2034 (US$ Million)
6.4.2 Market Share by Region, 2024 & 2034 (%)
6.5 Intravenous
6.5.1 Market Size by Region, 2024-2034 (US$ Million)
6.5.2 Market Share by Region, 2024 & 2034 (%)
6.6 Subcutaneous
6.6.1 Market Size by Region, 2024-2034 (US$ Million)
6.6.2 Market Share by Region, 2024 & 2034 (%)

7 Anti-obesity Drugs Market Analysis by Distribution Channel
7.1 Key Findings
7.2 Distribution Channel Segment: Market Attractiveness Index
7.3 Anti-obesity Drugs Market Size Estimation and Forecast by Distribution Channel
7.4 Hospital Pharmacies
7.4.1 Market Size by Region, 2024-2034 (US$ Million)
7.4.2 Market Share by Region, 2024 & 2034 (%)
7.5 Retail Pharmacies
7.5.1 Market Size by Region, 2024-2034 (US$ Million)
7.5.2 Market Share by Region, 2024 & 2034 (%)
7.6 Online Pharmacies
7.6.1 Market Size by Region, 2024-2034 (US$ Million)
7.6.2 Market Share by Region, 2024 & 2034 (%)

8 Anti-obesity Drugs Market Analysis by Region
8.1 Key Findings
8.2 Regional Market Size Estimation and Forecast

9 North America Anti-obesity Drugs Market Analysis
9.1 Key Findings
9.2 North America Anti-obesity Drugs Market Attractiveness Index
9.3 North America Anti-obesity Drugs Market by Country, 2024, 2029 & 2034 (US$ Million)
9.4 North America Anti-obesity Drugs Market Size Estimation and Forecast by Country
9.5 North America Anti-obesity Drugs Market Size Estimation and Forecast by Drug Type
9.6 North America Anti-obesity Drugs Market Size Estimation and Forecast by Mechanism of Action
9.7 North America Anti-obesity Drugs Market Size Estimation and Forecast by Route of Administration
9.8 North America Anti-obesity Drugs Market Size Estimation and Forecast by Distribution Channel
9.9 U.S. Anti-obesity Drugs Market Analysis
9.10 Canada Anti-obesity Drugs Market Analysis

10 Europe Anti-obesity Drugs Market Analysis
10.1 Key Findings
10.2 Europe Anti-obesity Drugs Market Attractiveness Index
10.3 Europe Anti-obesity Drugs Market by Country, 2024, 2029 & 2034 (US$ Million)
10.4 Europe Anti-obesity Drugs Market Size Estimation and Forecast by Country
10.5 Europe Anti-obesity Drugs Market Size Estimation and Forecast by Drug Type
10.6 Europe Anti-obesity Drugs Market Size Estimation and Forecast by Mechanism of Action
10.7 Europe Anti-obesity Drugs Market Size Estimation and Forecast by Route of Administration
10.8 Europe Anti-obesity Drugs Market Size Estimation and Forecast by Distribution Channel
10.9 Germany Anti-obesity Drugs Market Analysis
10.10 France Anti-obesity Drugs Market Analysis
10.11 UK Anti-obesity Drugs Market Analysis
10.12 Italy Anti-obesity Drugs Market Analysis
10.13 Spain Anti-obesity Drugs Market Analysis
10.14 Russia Anti-obesity Drugs Market Analysis
10.15 Poland Anti-obesity Drugs Market Analysis
10.16 Belgium Anti-obesity Drugs Market Analysis
10.17 Rest of Europe Anti-obesity Drugs Market Analysis

11 Asia Pacific Anti-obesity Drugs Market Analysis
11.1 Key Findings
11.2 Asia Pacific Anti-obesity Drugs Market Attractiveness Index
11.3 Asia Pacific Anti-obesity Drugs Market by Country, 2024, 2029 & 2034 (US$ Million)
11.4 Asia Pacific Anti-obesity Drugs Market Size Estimation and Forecast by Country
11.5 Asia Pacific Anti-obesity Drugs Market Size Estimation and Forecast by Drug Type
11.6 Asia Pacific Anti-obesity Drugs Market Size Estimation and Forecast by Mechanism of Action
11.7 Asia Pacific Anti-obesity Drugs Market Size Estimation and Forecast by Route of Administration
11.8 Asia Pacific Anti-obesity Drugs Market Size Estimation and Forecast by Distribution Channel
11.9 Japan Anti-obesity Drugs Market Analysis
11.10 China Anti-obesity Drugs Market Analysis
11.11 India Anti-obesity Drugs Market Analysis
11.12 Australia Anti-obesity Drugs Market Analysis
11.13 South Korea Anti-obesity Drugs Market Analysis
11.14 Singapore Anti-obesity Drugs Market Analysis
11.15 Taiwan Anti-obesity Drugs Market Analysis
11.16 Rest of Asia Pacific Anti-obesity Drugs Market Analysis

12 Latin America Anti-obesity Drugs Market Analysis
12.1 Key Findings
12.2 Latin America Anti-obesity Drugs Market Attractiveness Index
12.3 Latin America Anti-obesity Drugs Market by Country, 2024, 2029 & 2034 (US$ Million)
12.4 Latin America Anti-obesity Drugs Market Size Estimation and Forecast by Country
12.5 Latin America Anti-obesity Drugs Market Size Estimation and Forecast by Drug Type
12.6 Latin America Anti-obesity Drugs Market Size Estimation and Forecast by Mechanism of Action
12.7 Latin America Anti-obesity Drugs Market Size Estimation and Forecast by Route of Administration
12.8 Latin America Anti-obesity Drugs Market Size Estimation and Forecast by Distribution Channel
12.9 Brazil Anti-obesity Drugs Market Analysis
12.10 Mexico Anti-obesity Drugs Market Analysis
12.11 Argentina Anti-obesity Drugs Market Analysis
12.12 Colombia Anti-obesity Drugs Market Analysis
12.13 Rest of Latin America Anti-obesity Drugs Market Analysis

13 MEA Anti-obesity Drugs Market Analysis
13.1 Key Findings
13.2 MEA Anti-obesity Drugs Market Attractiveness Index
13.3 MEA Anti-obesity Drugs Market by Country, 2024, 2029 & 2034 (US$ Million)
13.4 MEA Anti-obesity Drugs Market Size Estimation and Forecast by Country
13.5 MEA Anti-obesity Drugs Market Size Estimation and Forecast by Drug Type
13.6 MEA Anti-obesity Drugs Market Size Estimation and Forecast by Mechanism of Action
13.7 MEA Anti-obesity Drugs Market Size Estimation and Forecast by Route of Administration
13.8 MEA Anti-obesity Drugs Market Size Estimation and Forecast by Distribution Channel
13.9 GCC Anti-obesity Drugs Market Analysis
13.10 South Africa Anti-obesity Drugs Market Analysis
13.11 Rest of MEA Anti-obesity Drugs Market Analysis

14 Company Profiles
14.1 Competitive Landscape, 2022
14.2 Summary of all Strategic Outlook
14.3 Arena Pharmaceuticals Ltd.
14.3.1 Company Snapshot
14.3.2 Company Overview
14.3.3 Financial Analysis
14.3.3.1 Net Revenue, 2017-2022
14.3.3.2 R&D, 2017-2022
14.3.3.3 Regional Market Shares, 2022
14.3.4 Product Benchmarking
14.3.5 Strategic Outlook
14.4 Bayer AG
14.4.1 Company Snapshot
14.4.2 Company Overview
14.4.3 Financial Analysis
14.4.3.1 Net Revenue, 2017-2023
14.4.3.2 R&D, 2017-2023
14.4.3.3 Regional Market Shares, 2023
14.4.4 Product Benchmarking
14.4.5 Strategic Outlook
14.5 Boehringer Ingelheim International GmbH
14.5.1 Company Snapshot
14.5.2 Company Overview
14.5.3 Financial Analysis
14.5.3.1 Net Revenue, 2017-2022
14.5.3.2 R&D, 2017-2022
14.5.3.3 Regional Market Shares, 2022
14.5.4 Product Benchmarking
14.5.5 Strategic Outlook
14.6 Carmot Therapeutics, Inc.
14.6.1 Company Snapshot
14.6.2 Company Overview
14.6.3 Product Benchmarking
14.6.4 Strategic Outlook
14.7 CHEPLAPHARM Arzneimittel GmbH
14.7.1 Company Snapshot
14.7.2 Company Overview
14.7.3 Product Benchmarking
14.7.4 Strategic Outlook
14.8 CohBar, Inc.
14.8.1 Company Snapshot
14.8.2 Company Overview
14.8.3 Product Benchmarking
14.8.4 Strategic Outlook
14.9 Curaxx Pharmaceuticals LLC
14.9.1 Company Snapshot
14.9.2 Company Overview
14.9.3 Product Benchmarking
14.9.4 Strategic Outlook
14.10 Eisai Co., Ltd.
14.10.1 Company Snapshot
14.10.2 Company Overview
14.10.3 Financial Analysis
14.10.3.1 Net Revenue, 2017-2022
14.10.3.2 R&D, 2017-2022
14.10.3.3 Regional Market Shares, 2022
14.10.4 Product Benchmarking
14.10.5 Strategic Outlook
14.11 Eli Lilly and Co
14.11.1 Company Snapshot
14.11.2 Company Overview
14.11.3 Financial Analysis
14.11.3.1 Net Revenue, 2017-2023
14.11.3.2 R&D, 2017-2023
14.11.3.3 Regional Market Shares, 2023
14.11.4 Product Benchmarking
14.11.5 Strategic Outlook
14.12 F. Hoffmann-La Roche Ltd
14.12.1 Company Snapshot
14.12.2 Company Overview
14.12.3 Financial Analysis
14.12.3.1 Net Revenue, 2017-2022
14.12.3.2 R&D, 2017-2022
14.12.4 Product Benchmarking
14.12.5 Strategic Outlook
14.13 GlaxoSmithKline Plc
14.13.1 Company Snapshot
14.13.2 Company Overview
14.13.3 Financial Analysis
14.13.3.1 Net Revenue, 2017-2023
14.13.3.2 R&D, 2017-2023
14.13.3.3 Regional Market Shares, 2023
14.13.4 Product Benchmarking
14.13.5 Strategic Outlook
14.14 Hanmi Pharm Co., Ltd.
14.14.1 Company Snapshot
14.14.2 Company Overview
14.14.3 Financial Analysis
14.14.3.1 Net Revenue, 2017-2022
14.14.4 Product Benchmarking
14.14.5 Strategic Outlook
14.15 Merck & Co., Inc.
14.15.1 Company Snapshot
14.15.2 Company Overview
14.15.3 Financial Analysis
14.15.3.1 Net Revenue, 2017-2023
14.15.3.2 R&D, 2017-2023
14.15.3.3 Regional Market Shares, 2023
14.15.4 Product Benchmarking
14.15.5 Strategic Outlook
14.16 Novo Nordisk A/S
14.16.1 Company Snapshot
14.16.2 Company Overview
14.16.3 Financial Analysis
14.16.3.1 Net Revenue, 2017-2022
14.16.3.2 R&D, 2017-2022
14.16.3.3 Regional Market Shares, 2022
14.16.4 Product Benchmarking
14.16.5 Strategic Outlook
14.17 Pfizer Inc.
14.17.1 Company Snapshot
14.17.2 Company Overview
14.17.3 Financial Analysis
14.17.3.1 Net Revenue, 2017-2023
14.17.3.2 R&D, 2017-2023
14.17.3.3 Regional Market Shares, 2022
14.17.4 Product Benchmarking
14.17.5 Strategic Outlook
14.18 Rhythm Pharmaceuticals, Inc.
14.18.1 Company Snapshot
14.18.2 Company Overview
14.18.3 Financial Analysis
14.18.3.1 Net Revenue, 2017-2022
14.18.3.2 R&D, 2017-2022
14.18.3.3 Regional Market Shares, 2022
14.18.4 Product Benchmarking
14.18.5 Strategic Outlook
14.19 Takeda Pharmaceutical Company Limited
14.19.1 Company Snapshot
14.19.2 Company Overview
14.19.3 Financial Analysis
14.19.3.1 Net Revenue, 2017-2023
14.19.3.2 R&D, 2017-2023
14.19.3.3 Regional Market Shares, 2023
14.19.4 Product Benchmarking
14.19.5 Strategic Outlook
14.20 VIVUS LLC
14.20.1 Company Snapshot
14.20.2 Company Overview
14.20.3 Financial Analysis
14.20.3.1 Net Revenue, 2017-2023
14.20.3.2 R&D, 2017-2019
14.20.3.3 Regional Market Shares, 2023
14.20.4 Product Benchmarking
14.20.5 Strategic Outlook
14.21 Zydus Lifesciences
14.21.1 Company Snapshot
14.21.2 Company Overview
14.21.3 Financial Analysis
14.21.3.1 Net Revenue, 2017-2023
14.21.3.2 R&D, 2017-2023
14.21.3.3 Regional Market Shares, 2023
14.21.4 Product Benchmarking
14.21.5 Strategic Outlook

15 Conclusion and Recommendations
15.1 Concluding Remarks from Visiongain
15.2 Recommendations for Market Players
 
List of Tables
Table 1 Anti-obesity Drugs Market Snapshot, 2024 & 2034 (US$ Million, CAGR %)
Table 2 Anti-obesity Drugs Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%): “V” Shaped Recovery
Table 3 Anti-obesity Drugs Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%): “U” Shaped Recovery
Table 4 Anti-obesity Drugs Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%): “W” Shaped Recovery
Table 5 Anti-obesity Drugs Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%): “L” Shaped Recovery
Table 6 Anti-obesity Drugs Market Drug Type, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 7 Prescription Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 8 OTC Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 9 Anti-obesity Drugs Market by Mechanism of Action, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 10 GLP-1 Agonists Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 11 GIPR Antagonists Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 12 Amylin Receptor Agonist Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 13 Lipase Inhibitors Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 14 SNRI’s Agonists Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 15 Others Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 16 Anti-obesity Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 17 Oral Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 18 Intravenous Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 19 Subcutaneous Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 20 Anti-obesity Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 21 Hospital Pharmacies Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 22 Retail Pharmacies Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 23 Online Pharmacies Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 24 Anti-obesity Drugs Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 25 North America Anti-obesity Drugs Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 26 North America Anti-obesity Drugs Market Drug Type, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 27 North America Anti-obesity Drugs Market Mechanism of Action, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 28 North America Anti-obesity Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 29 North America Anti-obesity Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 30 U.S. Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 31 Canada Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 32 Europe Anti-obesity Drugs Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 33 Europe Anti-obesity Drugs Market Drug Type, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 34 Europe Anti-obesity Drugs Market Mechanism of Action, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 35 Europe Anti-obesity Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 36 Europe Anti-obesity Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 37 Germany Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 38 France Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 39 UK Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 40 Italy Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 41 Spain Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 42 Russia Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 43 Poland Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 44 Belgium Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 45 Rest of Europe Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 46 Asia Pacific Anti-obesity Drugs Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 47 Asia Pacific Anti-obesity Drugs Market Drug Type, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 48 Asia Pacific Anti-obesity Drugs Market Mechanism of Action, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 49 Asia Pacific Anti-obesity Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 50 Asia Pacific Anti-obesity Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 51 Japan Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 52 China Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 53 India Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 54 Australia Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 55 South Korea Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 56 Singapore Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 57 Taiwan Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 58 Rest of Asia Pacific Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 59 Latin America Anti-obesity Drugs Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 60 Latin America Anti-obesity Drugs Market Drug Type, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 61 Latin America Anti-obesity Drugs Market Mechanism of Action, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 62 Latin America Anti-obesity Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 63 Latin America Anti-obesity Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 64 Brazil Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 65 Mexico Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 66 Argentina Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 67 Colombia Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 68 Rest of Latin America Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 69 MEA Anti-obesity Drugs Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 70 MEA Anti-obesity Drugs Market Drug Type, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 71 MEA Anti-obesity Drugs Market Mechanism of Action, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 72 MEA Anti-obesity Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 73 MEA Anti-obesity Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 74 GCC Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 75 South Africa Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 76 Rest of MEA Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 77 Strategic Outlook
Table 78 Arena Pharmaceuticals Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 79 Arena Pharmaceuticals Ltd.: Product Benchmarking
Table 80 Arena Pharmaceuticals Ltd.: Strategic Outlook
Table 81 Bayer AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 82 Bayer AG: Product Benchmarking
Table 83 Bayer AG: Strategic Outlook
Table 84 Boehringer Ingelheim International GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 85 Boehringer Ingelheim International GmbH: Product Benchmarking
Table 86 Boehringer Ingelheim International GmbH: Strategic Outlook
Table 87 Carmot Therapeutics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 88 Carmot Therapeutics, Inc.: Product Benchmarking
Table 89 Carmot Therapeutics, Inc.: Strategic Outlook
Table 90 CHEPLAPHARM Arzneimittel GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 91 CHEPLAPHARM Arzneimittel GmbH.: Product Benchmarking
Table 92 CHEPLAPHARM Arzneimittel GmbH.: Strategic Outlook
Table 93 CohBar, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 94 CohBar, Inc.: Product Benchmarking
Table 95 CohBar, Inc.: Strategic Outlook
Table 96 Curaxx Pharmaceuticals LLC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 97 Curaxx Pharmaceuticals LLC: Product Benchmarking
Table 98 Curaxx Pharmaceuticals LLC: Strategic Outlook
Table 99 Eisai Co. Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 100 Eisai Co. Ltd: Product Benchmarking
Table 101 Eisai Co. Ltd: Strategic Outlook
Table 102 Eli Lilly and Co: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 103 Eli Lilly and Co: Product Benchmarking
Table 104 Eli Lilly and Co: Strategic Outlook
Table 105 F. Hoffmann-La Roche Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 106 F. Hoffmann-La Roche Ltd.: Product Benchmarking
Table 107 F. Hoffmann-La Roche Ltd: Strategic Outlook
Table 108 GlaxoSmithKline Plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 109 GlaxoSmithKline Plc: Product Benchmarking
Table 110 GlaxoSmithKline Plc: Strategic Outlook
Table 111 Hanmi Pharm Co., Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 112 Hanmi Pharm Co., Ltd.: Product Benchmarking
Table 113 Hanmi Pharm Co., Ltd.: Strategic Outlook
Table 114 Merck & Co., Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 115 Merck & Co., Inc.: Product Benchmarking
Table 116 Merck & Co., Inc.: Strategic Outlook
Table 117 Novo Nordisk A/S: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 118 Novo Nordisk A/S: Product Benchmarking
Table 119 Novo Nordisk A/S: Strategic Outlook
Table 120 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 121 Pfizer Inc.: Product Benchmarking
Table 122 Pfizer Inc.: Strategic Outlook
Table 123 Rhythm Pharmaceuticals, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 124 Rhythm Pharmaceuticals, Inc.: Product Benchmarking
Table 125 Rhythm Pharmaceuticals, Inc.: Strategic Outlook
Table 126 Takeda Pharmaceutical Company Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 127 Takeda Pharmaceutical Company Limited: Product Benchmarking
Table 128 Takeda Pharmaceutical Company Limited: Strategic Outlook
Table 129 VIVUS LLC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 130 VIVUS LLC: Product Benchmarking
Table 131 VIVUS LLC: Strategic Outlook
Table 132 Zydus Lifesciences: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 133 Zydus Lifesciences: Product Benchmarking
Table 134 Zydus Lifesciences: Strategic Outlook

List of Figures
Figure 1 Anti-obesity Drugs Market Segmentation
Figure 2 Anti-obesity Drugs Market by Route of Administration: Market Attractiveness Index
Figure 3 Anti-obesity Drugs Market by Distribution Channel: Market Attractiveness Index
Figure 4 Anti-obesity Drugs Mechanism of Action: Market Attractiveness Index
Figure 5 Anti-obesity Drugs Market by Drug Type: Market Attractiveness Index
Figure 6 Anti-obesity Drugs Market Attractiveness Index by Region
Figure 7 Anti-obesity Drugs Market: Market Dynamics
Figure 8 Top 10 Most Obese Countries in the World
Figure 9 Prevalence of Obesity in Different Regions
Figure 10 Top Anti-obesity Products by Revenue, 2022
Figure 11 Anti-obesity Product Pipeline Analysis by Phase
Figure 12 Anti-obesity Products, New Product Launches
Figure 13 Anti-obesity Drugs Market by Region, 2024-2034 (US$ Million, AGR %): “V” Shaped Recovery
Figure 14 Anti-obesity Drugs Market by Region, 2024-2034 (US$ Million, AGR %): “U” Shaped Recovery
Figure 15 Anti-obesity Drugs Market by Region, 2024-2034 (US$ Million, AGR %): “W” Shaped Recovery
Figure 16 Anti-obesity Drugs Market by Region, 2024-2034 (US$ Million, AGR %): “L” Shaped Recovery
Figure 17 Anti-obesity Drugs Market: Porter’s Five Forces Analysis
Figure 18 Anti-obesity Drugs Market: PEST Analysis
Figure 19 Anti-obesity Drugs Market by Drug Type: Market Attractiveness Index
Figure 20 Anti-obesity Drugs Market Forecast by Drug Type, 2024-2034 (US$ Million, AGR %)
Figure 21 Anti-obesity Drugs Market Share Forecast by Drug Type 2024, 2029, 2034 (%)
Figure 22 Prescription Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 23 Prescription Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 24 OTC Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 25 OTC Market Share Forecast by Region, 2024 & 2034 (%)
Figure 26 Anti-obesity Drugs Market by Mechanism of Action: Market Attractiveness Index
Figure 27 Anti-obesity Drugs Market Forecast by Mechanism of Action, 2024-2034 (US$ Million, AGR %)
Figure 28 Anti-obesity Drugs Market Share Forecast by Mechanism of Action; 2024, 2029, 2034 (%)
Figure 29 GLP-1 Agonists Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 30 GLP-1 Agonists Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 31 GIPR Antagonists Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 32 GIPR Antagonists Market Share Forecast by Region, 2024 & 2034 (%)
Figure 33 Amylin Receptor Agonist Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 34 Amylin Receptor Agonist Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 35 Lipase Inhibitors Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 36 Lipase Inhibitors Market Share Forecast by Region, 2024 & 2034 (%)
Figure 37 SNRI’s Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 38 SNRI’s Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 39 Others Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 40 Others Market Share Forecast by Region, 2024 & 2034 (%)
Figure 41 Anti-obesity Drugs Market by Route of Administration: Market Attractiveness Index
Figure 42 Anti-obesity Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)
Figure 43 Anti-obesity Drugs Market Share Forecast by Route of Administration, 2024, 2029, 2034 (%)
Figure 44 Oral Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 45 Oral Market Share Forecast by Region, 2024 & 2034 (%)
Figure 46 Intravenous Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 47 Intravenous Market Share Forecast by Region, 2024 & 2034 (%)
Figure 48 Subcutaneous Stimulator Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 49 Subcutaneous Stimulator Market Share Forecast by Region, 2024 & 2034 (%)
Figure 50 Anti-obesity Drugs Market by Distribution Channel: Market Attractiveness Index
Figure 51 Anti-obesity Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
Figure 52 Anti-obesity Drugs Market Share Forecast by Route of Administration, 2024, 2029, 2034 (%)
Figure 53 Hospital Pharmacies Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 54 Hospital Pharmacies Market Share Forecast by Region, 2024 & 2034 (%)
Figure 55 Retail Pharmacies Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 56 Retail Pharmacies Market Share Forecast by Region, 2024 & 2034 (%)
Figure 57 Online Pharmacies Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 58 Online Pharmacies Market Share Forecast by Region, 2024 & 2034 (%)
Figure 59 Anti-obesity Drugs Market Forecast by Region 2024 and 2034 (Revenue, CAGR %)
Figure 60 Anti-obesity Drugs Market Share Forecast by Region 2024, 2029, 2034 (%)
Figure 61 Anti-obesity Drugs Market by Region, 2024-2034 (US$ Million, AGR %)
Figure 62 North America Anti-obesity Drugs Market Attractiveness Index
Figure 63 North America Anti-obesity Drugs Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 64 North America Anti-obesity Drugs Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 65 North America Anti-obesity Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 66 North America Anti-obesity Drugs Market Forecast by Drugs, 2024-2034 (US$ Million, AGR %)
Figure 67 North America Anti-obesity Drugs Market Share Forecast by Drugs, 2024 & 2034 (%)
Figure 68 North America Anti-obesity Drugs Market Forecast by Mechanism of Action, 2024-2034 (US$ Million, AGR %)
Figure 69 North America Anti-obesity Drugs Market Share Forecast by Mechanism of Action, 2024 & 2034 (%)
Figure 70 North America Anti-obesity Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)
Figure 71 North America Anti-obesity Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 72 North America Anti-obesity Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
Figure 73 North America Anti-obesity Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 74 U.S. Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 75 Canada Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 76 Europe Anti-obesity Drugs Market Attractiveness Index
Figure 77 Europe Anti-obesity Drugs Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 78 Europe Anti-obesity Drugs Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 79 Europe Anti-obesity Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 80 Europe Anti-obesity Drugs Market Forecast by Drugs, 2024-2034 (US$ Million, AGR %)
Figure 81 Europe Anti-obesity Drugs Market Share Forecast by Drugs, 2024 & 2034 (%)
Figure 82 Europe Anti-obesity Drugs Market Forecast by Mechanism of Action, 2024-2034 (US$ Million, AGR %)
Figure 83 Europe Anti-obesity Drugs Market Share Forecast by Mechanism of Action, 2024 & 2034 (%)
Figure 84 Europe Anti-obesity Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)
Figure 85 Europe Anti-obesity Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 86 Europe Anti-obesity Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
Figure 87 Europe Anti-obesity Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 88 Germany Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 89 France Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 90 UK Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 91 Italy Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 92 Spain Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 93 Russia Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 94 Poland Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 95 Belgium Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 96 Rest of Europe Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 97 Asia Pacific Anti-obesity Drugs Market Attractiveness Index
Figure 98 Asia Pacific Anti-obesity Drugs Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 99 Asia Pacific Anti-obesity Drugs Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 100 Asia Pacific Anti-obesity Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 101 Asia Pacific Anti-obesity Drugs Market Forecast by Drugs Type, 2024-2034 (US$ Million, AGR %)
Figure 102 Asia Pacific Anti-obesity Drugs Market Share Forecast by Drugs Type, 2024 & 2034 (%)
Figure 103 Asia Pacific Anti-obesity Drugs Market Forecast by Mechanism of Action, 2024-2034 (US$ Million, AGR %)
Figure 104 Asia Pacific Anti-obesity Drugs Market Share Forecast by Mechanism of Action, 2024 & 2034 (%)
Figure 105 Asia Pacific Anti-obesity Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)
Figure 106 Asia Pacific Anti-obesity Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 107 Asia Pacific Anti-obesity Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
Figure 108 Asia Pacific Anti-obesity Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 109 Japan Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 110 China Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 111 India Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 112 Australia Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 113 South Korea Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 114 Singapore Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 115 Taiwan Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 116 Rest of Asia Pacific Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 117 Latin America Anti-obesity Drugs Market Attractiveness Index
Figure 118 Latin America Anti-obesity Drugs Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 119 Latin America Anti-obesity Drugs Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 120 Latin America Anti-obesity Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 121 Latin America Anti-obesity Drugs Market Forecast by Drugs type, 2024-2034 (US$ Million, AGR %)
Figure 122 Latin America Anti-obesity Drugs Market Share Forecast by Drug type, 2024 & 2034 (%)
Figure 123 Latin America Anti-obesity Drugs Market Forecast by Mechanism of Action, 2024-2034 (US$ Million, AGR %)
Figure 124 Latin America Anti-obesity Drugs Market Share Forecast by Mechanism of Action, 2024 & 2034 (%)
Figure 125 Latin America Anti-obesity Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)
Figure 126 Latin America Anti-obesity Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 127 Latin America Anti-obesity Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
Figure 128 Latin America Anti-obesity Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 129 Brazil Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 130 Mexico Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 131 Argentina Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 132 Colombia Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 133 Rest of Latin America Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 134 MEA Anti-obesity Drugs Market Attractiveness Index
Figure 135 MEA Anti-obesity Drugs Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 136 MEA Anti-obesity Drugs Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 137 MEA Anti-obesity Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 138 MEA Anti-obesity Drugs Market Forecast by Drug Type, 2024-2034 (US$ Million, AGR %)
Figure 139 MEA Anti-obesity Drugs Market Share Forecast by Drug Type, 2024 & 2034 (%)
Figure 140 MEA Anti-obesity Drugs Market Forecast by Mechanism of Action, 2024-2034 (US$ Million, AGR %)
Figure 141 MEA Anti-obesity Drugs Market Share Forecast by Mechanism of Action, 2024 & 2034 (%)
Figure 142 MEA Anti-obesity Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)
Figure 143 MEA Anti-obesity Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 144 MEA Anti-obesity Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
Figure 145 MEA Anti-obesity Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 146 GCC Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 147 South Africa Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 148 Rest of MEA Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 149 Anti-obesity Market Company Share, 2022
Figure 150 Arena Pharmaceuticals Ltd.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 151 Arena Pharmaceuticals Ltd.: R&D, 2017-2022 (US$ Million, AGR%)
Figure 152 Arena Pharmaceuticals Ltd.: Regional Market Shares, 2022
Figure 153 Bayer AG: Net Revenue, 2017-2023 (US$ Million, AGR%)
Figure 154 Bayer AG : R&D, 2017-2023 (US$ Million, AGR%)
Figure 155 Bayer AG: Regional Market Shares, 2023
Figure 156 Boehringer Ingelheim International GmbH: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 157 Boehringer Ingelheim International GmbH: R&D, 2017-2022 (US$ Million, AGR%)
Figure 158 Boehringer Ingelheim International GmbH: Regional Market Shares, 2022
Figure 159 Eisai Co. Ltd: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 160 Eisai Co. Ltd: R&D, 2017-2022 (US$ Million, AGR%)
Figure 161 Eisai Co. Ltd: Regional Market Shares, 2022
Figure 162 Eli Lilly and Co: Net Revenue, 2017-2023 (US$ Million, AGR%)
Figure 163 Eli Lilly and Co: R&D, 2017-2023 (US$ Million, AGR%)
Figure 164 Eli Lilly and Co: Regional Market Shares, 2023
Figure 165 F. Hoffmann-La Roche Ltd.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 166 F. Hoffmann-La Roche Ltd.: R&D, 2017-2022 (US$ Million, AGR%)
Figure 167 GlaxoSmithKline Plc: Net Revenue, 2017-2023 (US$ Million, AGR%)
Figure 168 GlaxoSmithKline Plc: R&D, 2017-2023 (US$ Million, AGR%)
Figure 169 GlaxoSmithKline Plc: Regional Market Shares, 2023
Figure 170 Hanmi Pharm Co., Ltd.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 171 Merck & Co., Inc.: Net Revenue, 2017-2023 (US$ Million, AGR%)
Figure 172 Merck & Co., Inc.: R&D, 2017-2023 (US$ Million, AGR%)
Figure 173 Merck & Co., Inc.: Regional Market Shares, 2023
Figure 174 Novo Nordisk A/S: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 175 Novo Nordisk A/S: R&D, 2017-2022 (US$ Million, AGR%)
Figure 176 Novo Nordisk A/S: Regional Market Shares, 2022
Figure 177 Pfizer Inc.: Net Revenue, 2017-2023 (US$ Million, AGR%)
Figure 178 Pfizer Inc.: R&D, 2017-2023 (US$ Million, AGR%)
Figure 179 Pfizer Inc. Regional Market Shares, 2022
Figure 180 Rhythm Pharmaceuticals, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 181 Rhythm Pharmaceuticals, Inc.: R&D, 2017-2022 (US$ Million, AGR%)
Figure 182 Rhythm Pharmaceuticals, Inc. Regional Market Shares, 2022
Figure 183 Takeda Pharmaceutical Company Limited: Net Revenue, 2017-2023 (US$ Million, AGR%)
Figure 184 Takeda Pharmaceutical Company Limited: R&D, 2017-2022 (US$ Million, AGR%)
Figure 185 Takeda Pharmaceutical Company Limited: Regional Market Shares, 2023
Figure 186 VIVUS LLC: Net Revenue, 2017-2023 (US$ Million, AGR%)
Figure 187 VIVUS LLC: R&D, 2017-2019 (US$ Million, AGR%)
Figure 188 VIVUS LLC: Regional Market Shares, 2023
Figure 189 Zydus Lifesciences: Net Revenue, 2017-2023 (US$ Million, AGR%)
Figure 190 Zydus Lifesciences: R&D, 2017-2023 (US$ Million, AGR%)
Figure 191 Zydus Lifesciences: Regional Market Shares, 2023